Skip to content

Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU

Characterization of the Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in the Intensive Care Unit

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04385004
Acronym
PR-Covid-19
Enrollment
320
Registered
2020-05-12
Start date
2020-04-27
Completion date
2020-07-31
Last updated
2020-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

ARDS, Covid-19, SARS-CoV-2, Inflammatory cytokine, Sepsis, ICU, Tbular necrosis, Ischemia, Pulmonary damage, Renal damage, Kidney damage

Brief summary

Renal damage in patients hospitalized for ARDS in the ICU can also be related to multiple causes including, but not limited to, the consequences of hemodynamic fluctuations in these patients or the use of nephrotoxic drugs responsible for acute post-ischemic or toxic tubular necrosis. Frequently observed abnormalities of cioagumation may also have a potential impact on renal structures, particularly glomerular capillaries. The researchers wish to characterize and phenotype the renal impairment of patients hospitalized in intensive care with tables of severe Covid19 infections in ARDS: clinical, biological and histological (by performing post-mortem biopsies). Translated with www.DeepL.com/Translator (free version)

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients over 18 years of age * Diagnosed Covid-19 by RT PCR * Hospitalized in intensive care for management of complications related to Covid-19 from March 1, 2020 to April 20, 2020 * Patient not having expressed his or her opposition, after information, to the re-use of his or her data for the purposes of this research.

Exclusion criteria

\- Subject who expressed opposition to participating in the study

Design outcomes

Primary

MeasureTime frame
Analysis of Clinical, Biological and Histological Pulmonary and Renal Impairment Related to SARS-CoV-21 month

Countries

France

Contacts

Primary ContactFerhat MEZIANI, MD, PhD
ferhat.meziani@chru-strasbourg.fr33 3 69 55 10 24
Backup ContactSaïd CHAYER, PhD, HDR
said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026